VivoSeq
Oncology

Astrocytoma

21

Pipeline Programs↗

5

Active Trials↗

13

Companies Involved↗

Astrocytoma is an emerging landscape with 21 programs across 13 companies. The most active players are Merck & Co., Eli Lilly, Neurocrine Biosciences. 2 therapies are approved with 3 more in late-stage development.

Intelligence

Pipeline Metrics

Competitive Density

48/100

Pipeline Velocity

11/100

Mech. Concentration

14/100

Completion Rate

69/100

Attrition Rate

20/100

Competition

Competitive Landscape

Bubble size = clinical trials

Approved
Phase 3
Phase 2
Phase 1
Preclinical

Key Players

Top Companies Companies ranked by the number of pipeline programs they run for this disease.

Merck & Co. logo

Merck & Co.

1 program

Phase 1Eli Lilly logo

Eli Lilly

1 program

Phase 1Neurocrine Biosciences logo

Neurocrine Biosciences

1 program

Phase 1BeiGene logo

BeiGene

1 program

Phase 2Bayer logo

Bayer

1 program

Phase 2S

Sagimet Biosciences Inc.

1 program

Phase 2

Pipeline

Programs by Phase

Analysis

Modality Breakdown

71%

Small molecule

15 of 21 classified programs — the dominant modality here.

29%ALL OTHERSMonoclonal antibody419%Vaccine210%

Small molecule leads; the ring shows all 21 classified programs, each share of the total. Modality classified for 100% of 23 pipeline programs.

Analysis

Trial Status

20

clinical trials

Completed9 · 45%
Terminated4 · 20%
Recruiting4 · 20%
Unknown status2 · 10%
Not yet recruiting1 · 5%

Clinical Trials

Trial Activity

20 trials

Adenovirus Mediated Suicide Gene Therapy With Radiotherapy in Progressive Astrocytoma.
Recruiting·HHenry Ford Health System·Phase 1·NCT05686798·18 enrolled
Tuvusertib in Astrocytoma With ATRX Mutation
Recruiting·GGrupo Español de Investigación en Neurooncología·Phase 2·NCT07417761·56 enrolled
Vorasidenib Maintenance for IDH Mutant Astrocytoma
Recruiting·EEuropean Organisation for Research and Treatment of Cancer - EORTC·Phase 3·NCT06809322·468 enrolled
A Phase I Hypofractionation Trial of Re-irradiation in Good Prognosis Recurrent Glioblastoma
Recruiting·National Cancer Institute (NCI)·Phase 1·NCT06344130·28 enrolled
Sintilimab (One Anti-PD-1 Antibody) Plus Low-dose Bevacizumab for ctDNAlevel- Relapse and Clinical-relapse Astrocytoma
Not yet recruiting·HHenan Provincial People's Hospital·Phase 2·NCT05518994·70 enrolled
TVB- 2640 in Combination With Bevacizumab in Patients With First Relapse of High Grade Astrocytoma
Completed·TThe University of Texas Health Science Center at San Antonio·Phase 2·NCT03032484·25 enrolled
Imaging Procedure Using ALA in Finding Residual Tumor in Grade IV Malignant Astrocytoma
Completed·—·Phase 2·NCT00752323·73 enrolled
Antineoplaston Therapy in Treating Children With Low-Grade Astrocytoma
Completed·—·Phase 2·NCT00003468·11 enrolled
Dose Evaluation Safety STudy IN Individuals With Astrocytoma Taking PolyMVA
Completed·SStony Brook University·Phase 1·NCT01833273·13 enrolled
Tadalafil to Overcome Immunosuppression During Chemoradiotherapy for IDH-wildtype Grade III-IV Astrocytoma
Completed·WWashington University School of Medicine·Phase 1·NCT04757662·18 enrolled
Safety and Efficacy Study of TH-302 CNS Penetration in Recurrent High Grade Astrocytoma Following Bevacizumab
Completed·TThe University of Texas Health Science Center at San Antonio·Phase 2·NCT01403610·28 enrolled
Radiotherapy for Malignant Astrocytomas in the Elderly
Completed·AAssistance Publique - Hôpitaux de Paris·Phase 3·NCT00430911
Phase III Trial of Primary Radio- or Chemotherapy in Malignant Astrocytoma of the Elderly
Completed·HHeidelberg University·Phase 3·NCT01502241·412 enrolled
Effects of Vaccinations With HLA-A2-Restricted Glioma Antigen-Peptides in Combination With Poly-ICLC for Adults With High-Risk WHO Grade II Astrocytomas and Oligo-Astrocytomas
Completed·IIan F. Pollack, M.D.·Phase 1·NCT00795457·13 enrolled
Antineoplaston Therapy in Treating Patients With Low-Grade Astrocytoma
Terminated·—·Phase 2·NCT00003471·7 enrolled
Page 1 of 2

Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)